期刊文献+

Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma 被引量:11

Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma
下载PDF
导出
摘要 Background and Objective:Although there are many randomized clinical trials of late course accelerated hyperfractionated radiotherapy (LCAHFR) combined with FP chemotherapy for esophageal cancer, the efficacy and toxicity are controversial. This study was to evaluate the efficacy and toxicity of LCAHFR combined with FP chemotherapy in treating esophageal cancer. Methods: Reports of randomized clinical trials on LCAHFR combined with FP chemotherapy for esophageal cancer published between January 1999 and January 2009 were researched through Wanfang, CNKI, and PubMed databases. RevMan4.2 software was used for Meta-analysis. Results: Twenty-one reports, including 2030 patients, were included in the meta-analysis. Of the 2030 patients, 1006 underwent LCAHFR (LCAHFR group), and 1024 underwent LCAHFR combined with FP chemotherapy (combination group). Compared with those of the LCAHFR group, the 1-, 2-, 3-, 5-years survival rates and 1-, 2-, 3-year local control rates of the combination group were significant increased, and the acute toxicity was also increased, but chronic toxicity showed no significant difference. C onclusions: LCAHFR combined with FP chemotherapy can improve the survival rate and the local control rate of the patients with esophageal cancer. The increased acute toxicity need to be concerned, whereas the chronic toxicity needs a long-term observation. Background and Objective: Although there are many randomized clinical trials of late course accelerated hyperfractionated radiotherapy (LCAHFR) combined with FP chemotherapy for esophageal cancer, the efficacy and toxicity are controversial. This study was to evaluate the efficacy and toxicity of LCAHFR combined with FP chemotherapy in treating esophageal cancer. Methods: Reports of randomized clinical trials on LCAHFR combined with FP chemotherapy for esophageal cancer published between January 1999 and January 2009 were researched through Wanfang, CNKI, and PubMed databases. RevMan4.2 software was used for Meta-analysis. Results: Twenty-one reports, including 2030 patients, were included in the meta-analysis. Of the 2030 patients, 1006 underwent LCAHFR (LCAHFR group), and 1024 underwent LCAHFR combined with FP chemotherapy (combination group). Compared with those of the LCAHFR group, the 1-, 2-, 3-, 5-years survival rates and 1-, 2-, 3-year local control rates of the combination group were significant increased, and the acute toxicity was also increased, but chronic toxicity showed no significant difference. Conclusions: LCAHFR combined with FP chemotherapy can improve the survival rate and the local control rate of the patients with esophageal cancer. The increased acute toxicity need to be concerned, whereas the chronic toxicity needs a long-term observation.
出处 《Chinese Journal of Cancer》 SCIE CAS CSCD 北大核心 2010年第10期889-899,共11页
关键词 食管癌 化疗 分割 PubMed数据库 Meta分析 急性毒性 放疗 计划生育 Esophageal neoplasm, late course accelerated hyperfractionation, radiotherapy, chemotherapy, Meta-analysis
  • 引文网络
  • 相关文献

参考文献19

二级参考文献64

共引文献364

同被引文献51

  • 1黄晓东,易俊林,高黎,徐国镇,金晶,杨伟志,卢泰祥,吴少雄,吴仁瑞,胡伟汉,谢伟长,韩非,高远红,高剑铭,潘建基,陈传本,朗锦义,李涛,董昱,付玉彬,樊林,李柏森,黎静,王晓怀,陈炳旭,高献书,张萍,吴湘玮,胡炳强.抗表皮生长因子受体单克隆抗体h—R3联合放疗治疗晚期鼻咽癌的Ⅱ期临床研究[J].中华肿瘤杂志,2007,29(3):197-201. 被引量:100
  • 2吴仁瑞,吴少雄,赵充,谢方云,高剑铭,胡伟汉,高远红,李凤岩,崔甜甜,卢泰祥.h-R3联合放疗治疗局部晚期鼻咽癌的Ⅱ期临床研究[J].癌症,2007,26(8):874-879. 被引量:24
  • 3K.Fakhrian,J.Heilmann,T.Schuster,R.Thamm,W.Reuschel,M.Molls,H.Geinitz.Primary radiotherapy with or without chemotherapy in non‐metastatic esophageal squamous cell carcinoma: a retrospective study[J].Diseases of the Esophagus.2012(3)
  • 4Urs Zingg.Outcome for esophageal cancer following treatment with chemotherapy and radiotherapy but not esophagectomy: nonsurgical treatment of esophageal cancer[J].Clinical and Experimental Gastroenterology (default).2009(default)
  • 5陈东福等著,殷蔚伯,谷铣之主编.肿瘤放射治疗学[M]. 中国协和医科大学出版社, 2002
  • 6Chen W,He Y,Zheng R,Zhang S,Zeng H,Zou X,He J.Esophageal cancer incidence and mortality in China,2009[].J Thorac Dis.2013
  • 7HERSKOVIC A,RUSSELL W,LIPTAY M,et al.Esophage-al carcinoma advances in treatment results for locally advanceddisease:review[].Annals of Oncology:Official Journal ofthe European Society for Medical Oncology/ESMO.2012
  • 8Bidoli P,Bajetta E,Stani S C,et al.Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus[].Cancer.2002
  • 9Racette AL,Miller RT.Esophageal carcinoma:matching patients with treatment methods[].JAAPA.2011
  • 10Zhu WG,Zhou K,Yu CH,et al.Efficacy analysis of simplifiedintensity-modulated radiotherapy with high or conventional doseand concurrent chemotherapy for patients with neck and upperthoracic esophageal carcinoma[].Asian Pacific Journal of Cancer Prevention.2012

引证文献11

二级引证文献125

;
使用帮助 返回顶部